Management of hyperlipidemia of kidney disease.
Grundy
S M
SM
Department of Internal Medicine and Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235-9052.
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000209:etiology; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000209:etiology*; D007676:Kidney Failure, Chronic / Q000150:complications*; D016030:Kidney Transplantation / Q000009:adverse effects*; D009404:Nephrotic Syndrome / Q000150:complications*; D009525:Niacin / Q000627:therapeutic use; D011341:Probucol / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin; D011341:Probucol